SeaStar Medical Granted FDA Breakthrough Device Designation for a Novel Immunomodulatory Therapy for Acute Kidney Injury Patients

Designation can help empower accelerated regulatory overview of future pivotal medical demo for remedy in grownup clients with acute kidney injuries

DENVER, CO and TAMPA, FL, Might 03, 2022 (Globe NEWSWIRE) — SeaStar Healthcare, a clinical technological know-how organization producing proprietary answers to cut down the repercussions of hyperinflammation on critical organs, and LMF Acquisition Options, Inc. (Nasdaq: LMAO) (“LMAO”), a unique function acquisition organization, currently declared that SeaStar Medical’s Selective Cytopheretic Machine (SCD) has gained a Breakthrough Device Designation from the U.S. Food stuff and Drug Administration (Food and drug administration).

The SCD is a patented, cell-directed, extracorporeal immunomodulator that selectively targets activated neutrophils and monocytes to address hyperinflammation. Neutrophils and monocytes are the cellular mediators that push systemic inflammation, which when spreading uncontrollably by way of the physique can lead to organ injury, organ failure or death. The SCD technologies targets the mobile drivers of swelling to restore immune stability in the body and perhaps reverse the harm.

The Breakthrough Device Designation acknowledges our platform’s probable to tackle 1 of the biggest unmet clinical needs in handling acute kidney injuries,” claimed Eric Schlorff, President and Main Executive Officer of SeaStar Healthcare. “The scientific info produced to date in the two grown ups and pediatrics, has demonstrated a reduction of mortality and dialysis dependency in this critically-sick individual populace. We glance ahead to working with the Food and drug administration to deliver a novel remedy that addresses activated neutrophils and monocytes.”

The Breakthrough System Designation is predicted to enable expedited regulatory evaluate to progress SeaStar Medical’s forthcoming pivotal scientific demo for procedure of acute kidney personal injury (AKI) in older people.

In accordance to The Economic Outcomes of Acute Kidney Injury by Nephron in 2017, AKI is affiliated with an maximize in hospitalization fees that are approximated between $5.4 and $24. billion each year in the United States. As a end result, SeaStar Clinical estimates a multi billion greenback preliminary focus on market place in the US for the SCD, with likely for enlargement into acute respiratory distress syndrome (ARDS), extracorporeal membrane oxygenation (ECMO) and other indications.

Story continues

“This breakthrough designation need to help speed up the FDA’s timeline all around taking into consideration the SCD’s forthcoming IDE approval for use with acute kidney injuries sufferers,” explained Eric Schlorff. “Hyperinflammation can be a devastating component in lots of sicknesses such as acute kidney injuries, Covid-19 and acute respiratory distress syndrome. If accredited, the SCD would supply clinicians a powerful weapon to enable lower the effects of hyperinflammation and likely save life.”

As previously introduced, SeaStar Clinical and LMAO entered into a definitive settlement for a business mixture transaction whereby SeaStar Professional medical will become publicly detailed on Nasdaq, subject matter to acceptance by stockholders of LMAO and other customary closing circumstances.

About SeaStar Health care, Inc.

Denver-centered SeaStar Healthcare is a privately held health care engineering company that is focusing on redefining how extracorporeal therapies might lower the penalties of abnormal irritation on vital organs. SeaStar Medical’s novel technologies rely on science and innovation to deliver lifetime-saving solutions to critically ill patients. It is creating and commercializing extracorporeal therapies that focus on the effector cells that travel systemic irritation, leading to immediate tissue harm and secreting a variety of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. For more info stop by http://www.seastarmedical.com/ or visit us on LinkedIn or Twitter.

About LMF Acquisition Chances, Inc.

LMF Acquisition Prospects, Inc. (Nasdaq: LMAO) is a exclusive function acquisition enterprise shaped for the reason of effecting a merger, capital stock trade, asset acquisition, inventory invest in, reorganization or identical business blend with 1 or extra corporations. LMAO is led by Bruce M. Rodgers, Chief Executive Officer and Chairman of the Board. For a lot more information and facts, check out www.lmfacquisitions.com.

Forward-Hunting Statements

This push release incorporates sure forward-wanting statements in just the indicating of the “safe harbor” provisions of the Personal Securities Litigation Reform Act of 1955. These forward-searching statements contain, without limitation, LMAO’s and SeaStar Medical’s expectations with respect to the proposed business mixture among LMAO and SeaStar Health-related, together with statements relating to the advantages of the transaction, the anticipated timing of the transaction, the implied valuation of SeaStar Healthcare, the products supplied by SeaStar Health care and the markets in which it operates, and SeaStar Medical’s projected long term results. Words such as “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue on,” “will likely consequence,” and identical expressions are supposed to indentify these forward-on the lookout statements. Forward-hunting statements are predictions, projections and other statements about future gatherings that are dependent on present-day expectations and assumptions and, as a consequence, are topic to major hazards and uncertainties that could bring about the real benefits to differ materially from the anticipated final results. Most of these things are outdoors LMAO’s and SeaStar Medical’s management and are difficult to predict. Factors that may well cause real foreseeable future occasions to differ materially from the envisioned effects, contain, but are not restricted to: (i) the hazard that the business blend transaction amongst SeaStar Clinical and LMAO may not be accomplished in a timely way or at all, which may adversely affect the cost of LMAO’s securities, (ii) the danger that the transaction may not be concluded by LMAO’s business mixture deadline, even if extended by its sponsor, (iii) the failure to fulfill the disorders to the consummation of the transaction, including the adoption of the agreement and approach of merger (“Merger Agreement”) by the stockholders of LMAO and the pleasure of the bare minimum belief account volume subsequent redemptions by LMAO’s public stockholders, (iv) the incidence of any party, adjust or other circumstance that could give rise to the termination of the Merger Agreement, (v) the receipt of an unsolicited provide from yet another bash for an alternative transaction that could interfere with the business combination, (vi) the influence of the announcement or pendency of the transaction on SeaStar Medical’s business interactions, effectiveness, and business generally, (vii) the lack of ability to figure out the anticipated added benefits of the business mix, which might be influenced by, amongst other items, competitors and the capability of the publish-blend company to expand and handle development profitability and retain its important workers, (viii) costs similar to the business blend, (ix) the final result of any authorized proceedings that may well be instituted versus SeaStar Clinical or LMAO subsequent the announcement of the proposed business mixture, (x) the skill to preserve the listing of LMAO’s securities on the Nasdaq, (xi) the ability to put into practice business designs, forecasts, and other anticipations just after the completion of the proposed business combination, and determine and know added options, (xii) the threat of downturns and the likelihood of immediate modify in the highly competitive sector in which SeaStar Healthcare operates, (xiii) the threat that SeaStar Professional medical and its present and future collaborators are not able to efficiently acquire and commercialize SeaStar Medical’s products or solutions, or knowledge considerable delays in executing so, including failure to realize acceptance of its products by relevant federal and point out regulators, (xiv) the possibility that SeaStar Clinical may possibly under no circumstances reach or maintain profitability (xv) the chance that SeaStar Health-related might have to have to increase extra cash to execute its business plan, which many not be obtainable on acceptable phrases or at all (xvi) the chance that 3rd-functions suppliers and brands are not equipped to thoroughly and timely fulfill their obligations, (xvii) the hazard of product liability or regulatory lawsuits or proceedings relating to SeaStar Medical’s products and solutions and solutions, (xviii) the chance that SeaStar Healthcare is not able to protected or secure its mental residence, (xix) the chance that the submit-blend company’s securities will not be authorized for listing on Nasdaq or if authorised, keep the listing and (xx) other pitfalls and uncertainties indicated from time to time in the proxy statement / prospectus to be submitted relating to the business mix, which include those below the “Risk Factors” area therein and in LMAO’s other filings with the SEC. The foregoing record of aspects is not exhaustive. Forward-seeking statements discuss only as of the day they are made. Readers are cautioned not to put undue reliance on ahead-looking statements, and SeaStar Health-related and LMAO think no obligation and do not intend to update or revise these ahead-on the lookout statements, irrespective of whether as a final result of new data, potential functions, or otherwise.

Vital Info and Exactly where to Find It

In link with the business blend transaction, LMAO intends to file a registration statement on Type S-4 (the “Registration Statement”) with the SEC, which will consist of a preliminary proxy assertion to be distributed to holders of LMAO’s frequent stock in connection with LMAO’s solicitation of proxies for the vote by LMAO’s stockholders with respect to the transaction and other matters as described in the Registration Statement, as effectively as the prospectus relating to the offer you of the securities to be issued to SeaStar Medical’s stockholders in relationship with the transaction. Right after the Registration Statement has been filed and declared effective, LMAO will mail a definitive proxy assertion, when accessible, to its stockholders. Investors and security holders and other interested parties are urged to examine the proxy assertion/prospectus, any amendments thereto and any other paperwork filed with the SEC carefully and in their entirety when they come to be obtainable because they will contain crucial information about LMAO, SeaStar Health care and the transaction. Investors and safety holders may well receive absolutely free copies of the preliminary proxy statement/prospectus and definitive proxy assertion/prospectus (when accessible) and other documents filed with the U.S. Securities and Exchange Fee (the “SEC”) by LMAO by way of the web page managed by the SEC at http://www.sec.gov, or by directing a ask for to: LMF Acquisition Prospects, Inc., 1200 Platt Street, Suite 1000 Tampa, FL 33602.

Members in Solicitation

LMAO and SeaStar Medical and their respective directors and specific of their respective government officers and other members of management and personnel might be regarded as contributors in the solicitation of proxies with respect to the business mixture transaction. Details about the administrators and executive officers of LMAO is set forth in its Yearly Report on Sort 10-K for the fiscal calendar year ended December 31, 2021. Additional info regarding the contributors in the proxy solicitation and a description of their immediate and oblique pursuits, by safety holdings or normally, will be included in the proxy assertion/prospectus and other relevant materials to be submitted with the SEC regarding the business blend transaction when they turn out to be available. Stockholders, likely traders and other interested people must go through the proxy statement/prospectus very carefully when it turns into readily available just before making any voting or expense choices. When offered, these documents can be received totally free of cost from the sources indicated above.

No Give or Solicitation

This push release shall not represent an present to provide or the solicitation of an provide to get any securities, nor shall there be any sale of securities in any jurisdiction in which this kind of provide, solicitation or sale would be illegal prior to registration or qualification less than the securities regulations of any these kinds of jurisdiction. No supplying of securities shall be manufactured other than by signifies of a prospectus conference the specifications of Portion 10 of the U.S. Securities Act of 1933, as amended.

Media Relations Make contact with:
Patty Caballero
Email: [email protected]
Tel: 862.216.7523

Trader Relations Make contact with:
David Waldman or Natalya Rudman
Crescendo Communications, LLC
E mail: lmao@crescendo-ir.com
Tel: 212-671-1020